

REMARKS

Remarks regarding the Specification

The Examiner identified informalities regarding the SEQ. ID. NOS. to identify peptides in the specification on pages 3, 5, 6, 8, 9, 10, and 15. Please note that amendments to the specification correcting said informalities were made in Amendments dated January 29, 2003 and July 17, 2003.

The Examiner identified a clean copy of specification page 15 as a substitute. The Applicants did not indicate that said page was a substitute page. Hence, Applicants request that the Examiner withdraw her requirement for clean copy pages of 2-8 and 10-12 as substitute specification pages.

The Examiner requested that other informalities like those regarding peptide on specification pages 3, 5, 6, 8, 9, 10, and 15 also be corrected. As such, Applicant submits the above Amendments to the Specification for pages 11, 12, and 13 to correct informalities regarding identification of peptide with the corresponding SEQ. ID. NO.

An earnest attempt has been made hereby to respond to the informality objections contained in the October 21, 2003 Official Action. Withdrawal of the objections is hereby solicited. If the Examiner feels that a telephonic interview will rectify any misunderstandings with this matter, she is respectfully urged to contact the undersigned.

**Kappa-IV Recited in
Amended, New Claims**

Claims 1-13 and 15-22 are rejected under 35 U.S.C. 112, first paragraph for not enabling or providing a written description regarding the modification of *any* amyloid-forming protein. The Examiner stated that the specification is enabling and provides written description for kappa-IV immunoglobulin light chain manipulation. Amended claim 1 represents the embodiment the Examiner considers enabled and described.

Applicants have amended claim 1 to recite the kappa-IV protein. Claims 17-22 are canceled. New claims 29 and 31 recite kappa-IV.

In light of the foregoing amendment, Applicants request withdrawal of the §112,

first paragraph rejections and allowance of the pending claims.

Davis Reference Neither
Anticipates Nor Suggests

Claims 1-8, 10-13 and 15-22 are rejected under 35 U.S.C. 102(a) as being anticipated by Davis et al. (*J. Immunology* 163, pp 3842-50, Oct. 1999) Claims 1, 3 and 9 are rejected under 35 U.S.C. 102(a) as being unpatentable over Davis in view of Gardner, Schubert et al. or Ohashi et al. Applicants respectfully disagree.

Davis studied the interactions of binding protein BiP with naturally occurring substrate proteins. One of these naturally occurring substrate proteins was kappa-IV. The interactions studied in Davis did not result in fibril formation.

No discussion exists in Davis regarding fibril assembly, or the minimization or inhibition thereof.

Also, Davis does not teach *in vivo* processes. Rather, only *in vitro* processes are discussed in Davis (see page 3843, right column, second paragraph, lines 6-8, and page 3849, first sentence.).


Lastly, Davis does not teach peptides interacting with a protein, (wherein the peptides contain amino acid sequences also contained in the protein) so as to prevent fibril formation. This limitation is recited in newly added claim 34.

In light of the foregoing, Applicants request withdrawal of the §102 and §103 rejections based on Davis, and allowance of the pending claims.

An earnest attempt has been made hereby to respond to the FINAL Official Action dated October 21, 2003. All claims are deemed in condition for allowance. If the Examiner feels that a telephone interview will expedite allowance, she is respectfully urged to contact the undersigned. Previously submitted claims 1, 2, 5, 7, 10, 14-16, and newly added claims 23-34 are pending.

Respectfully submitted,

CHERSKOV & FLAYNIK

By 
Michael J. Cherskov (Reg. 33,664)